NextCure, Inc. (NASDAQ:NXTC) Short Interest Up 48.9% in January

NextCure, Inc. (NASDAQ:NXTC) saw a large growth in short interest in January. As of January 15th, there was short interest totaling 48,377 shares, a growth of 48.9% from the December 31st total of 32,483 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily volume of 32,544 shares, the short-interest ratio is presently 1.5 days. Based on an average daily volume of 32,544 shares, the short-interest ratio is presently 1.5 days. Currently, 1.6% of the company’s stock are short sold.

NextCure Stock Performance

NextCure stock opened at $10.85 on Friday. NextCure has a fifty-two week low of $2.69 and a fifty-two week high of $15.74. The stock has a market cap of $38.08 million, a price-to-earnings ratio of -0.45 and a beta of 1.52. The stock’s 50 day simple moving average is $12.56 and its two-hundred day simple moving average is $8.79.

NextCure (NASDAQ:NXTC) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($3.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.06) by $0.84. On average, analysts predict that NextCure will post -1.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of NextCure in a research report on Wednesday. LADENBURG THALM/SH SH raised NextCure from a “neutral” rating to a “buy” rating and set a $18.00 target price for the company in a report on Friday, November 7th. Finally, Wall Street Zen upgraded shares of NextCure to a “hold” rating in a research note on Saturday, December 13th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $23.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NextCure stock. Cable Car Capital LP lifted its holdings in NextCure, Inc. (NASDAQ:NXTC) by 13.1% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the period. Cable Car Capital LP owned about 28.29% of NextCure worth $349,000 at the end of the most recent reporting period. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.